32 Biosciences vs Adimab
32 Biosciences vs Adimab, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: 32 Biosciences is on 42/100 and Adimab on 53/100.
Where each one leads
32 Biosciences
Leads on none of the measures we hold for both companies.
Adimab
- our overall score: 53/100 against 42/100
- agent readiness: 40/100 against 21/100
- domain rating: 39/100 against 13/100
- headcount: 139 against 9
- funding raised: $105M against $12.0M
- LinkedIn following: 8,423 against 926
At a glance
| Measure | 32 Biosciences | Adimab |
|---|---|---|
| What it is | Develops novel therapeutic antibodies for oncology and autoimmune diseases. | Adimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform. |
| Category | Biotech, Drug Discovery, Oncology, Autoimmune Diseases | Biotech, Drug Discovery, Antibody Discovery, Therapeutic Antibodies |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Platform |
| Founded | 2017 | 2007 |
| Headquarters | San Diego, United States | Lebanon, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | 32 Biosciences | Adimab |
|---|---|---|
| Employees | 9 | 139 |
| Total funding | $12.0M | $105M |
| Latest round | Not published | Series B |
| LinkedIn followers | 926 | 8,423 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | 32 Biosciences | Adimab |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 42/100 | 53/100 |
| Traction | 45/100 | 60/100 |
| Team | 30/100 | Not published |
| Community | 3/100 | Not published |
| Search visibility | 24/100 | 20/100 |
| Quality | 48/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 13/100 | 39/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | 32 Biosciences | Adimab |
|---|---|---|
| Hosting | Self Managed | AWS |
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Jquery, Bootstrap |
| Analytics | Google Analytics 4 | Google Tag Manager, Linkedin Insight |
| Support stack | Not detected | HubSpot |
What users say
| Measure | 32 Biosciences | Adimab |
|---|---|---|
| Community ratingVisitor votes on StartupHub | 1.0/5 from 1 vote | Not published |
32 Biosciences vs Adimab: common questions
Which is better, 32 Biosciences or Adimab?
On our 0-100 score Adimab rates higher (53/100 against 42/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do 32 Biosciences and Adimab compare on the numbers?
Adimab leads on our overall score (53/100 against 42/100), agent readiness (40/100 against 21/100), domain rating (39/100 against 13/100), headcount (139 against 9), funding raised ($105M against $12.0M), LinkedIn following (8,423 against 926).
Read the full 32 Biosciences review and pricing or the Adimab review and pricing. You can also browse other 32 Biosciences alternatives we track.